| case report | Q2782326 |
| scholarly article | Q13442814 |
| P2093 | author name string | Kwang-Hyub Han | |
| Kun Ho Lee | |||
| Sang Hoon Ahn | |||
| Seung-Min Kim | |||
| Hana Park | |||
| Eun Hye Kim | |||
| P2860 | cites work | Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B. | Q43090485 |
| Polymyositis in patients taking antiviral clevudine therapy: a report of two cases | Q43142590 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases | Q44490128 | ||
| Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. | Q44960447 | ||
| Chronic hepatitis B--new goals, new treatment. | Q46217480 | ||
| Telbivudine in the treatment of the chronic B hepatitis | Q46649954 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| 18F-FDG PET/CT of drug-induced myopathy in a patient with chronic hepatitis B on long-term clevudine therapy. | Q53250596 | ||
| Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited | Q83764967 | ||
| Telbivudine: rhabdomyolysis and neuropathy | Q85186204 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 | ||
| Telbivudine for the management of chronic hepatitis B virus infection | Q33315189 | ||
| Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review | Q34128296 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. | Q34600796 | ||
| A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B. | Q34959568 | ||
| Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. | Q37576623 | ||
| Safety evaluation of telbivudine | Q37775959 | ||
| Telbivudine: a review of its use in compensated chronic hepatitis B. | Q37788209 | ||
| Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. | Q37934571 | ||
| Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. | Q38475543 | ||
| Myotoxicity of telbivudine in pre-existing muscle damage | Q41158138 | ||
| Clinical features of adverse reactions associated with telbivudine | Q41787869 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy | Q43064329 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | sibling | Q31184 |
| P304 | page(s) | 82-86 | |
| P577 | publication date | 2013-03-25 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. | |
| P478 | volume | 19 |
| Q28553983 | Clinicopathological Features of Telbivudine-Associated Myopathy |
| Q40910330 | Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine |
| Q45305692 | Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature |
| Q90703449 | Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination |
Search more.